Genentech Raptiva To Undergo 5,000-Patient Postmarketing Safety Study
Executive Summary
Genentech will conduct a 5,000-patient study of the incidence of adverse events associated with Raptiva (efalizumab) as a condition of FDA approval of the psoriasis treatment
You may also be interested in...
Phase IV Commitments For Registries Likely To Increase, Genentech Says
Manufacturers should expect more postmarketing commitments for safety and pregnancy exposure registries for chronic disease medications, Genentech Senior Epidemiologist Haley Kaplowitz, PhD, said during the Drug Information Association conference on pharmacovigilance in Washington, D.C. Jan. 14
Phase IV Commitments For Registries Likely To Increase, Genentech Says
Manufacturers should expect more postmarketing commitments for safety and pregnancy exposure registries for chronic disease medications, Genentech Senior Epidemiologist Haley Kaplowitz, PhD, said during the Drug Information Association conference on pharmacovigilance in Washington, D.C. Jan. 14
Genentech/Xoma Raptiva Clears FDA, Priced At 25% Discount to Amevive
Genentech/Xoma's psoriasis therapy Raptiva will be available by Thanksgiving at a 25% discount to a full year of Biogen's intramuscular injection formulation of Amevive